Bonjesta, as an antiemetic medication during pregnancy, commonly has anticholinergic reactions such as drowsiness and dry mouth, and serious adverse reactions require immediate medical attention. The following will explain from three aspects: common side effect management, identification of serious adverse reactions, and protection for special populations.

1. Common Side Effect Management

(1) Sleepiness: It is recommended to take medication before bedtime and avoid driving or operating machinery; Daytime medication can be divided into doses (such as half in the morning and half in the evening) to alleviate drowsiness.

(2) Dry mouth: Increase intake of sugar free beverages and use saliva substitutes; Avoid using alcohol mouthwash to worsen dryness.

(3) Dizziness: Slowly change position and lean against a support when getting up; The combined use of iron supplements may worsen symptoms and require monitoring.

2. Response to serious adverse reactions

(1) Allergic reaction: If there is swelling in the face/throat and difficulty breathing, the medication should be stopped immediately and emergency treatment should be sought. This medication should not be used in the future.

(2) Blurred consciousness: Elderly patients are more likely to experience it, and it is necessary to evaluate whether to combine anticholinergic drugs (such as tricyclic antidepressants).

(3) Urinary retention: patients with benign prostatic hyperplasia have an increased risk. It is recommended to urinate before medication, and catheterization is required in case of difficulty in urination.

3. Protection for special populations

(1) Pregnancy period: Although it is a Class B medication for pregnancy, its use in late pregnancy may cause excitement/tremors in newborns. It is recommended to discontinue the medication 2 weeks before delivery.

(2) Breastfeeding period: Medications can be secreted into breast milk, causing drowsiness or feeding difficulties in infants. It is recommended to suspend breastfeeding during the medication period.

(3) Liver damage: CYP2D6 slow metabolizers have elevated blood drug concentrations, requiring a 50% reduction and monitoring for excessive sedation symptoms.